Esophageal Diseases  >>  Avastin (bevacizumab)  >>  Phase 2
Welcome,         Profile    Billing    Logout  

11 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Avastin (bevacizumab) / Roche
NCT00137813: Avastin and Taxotere for Esophagogastric Cancer

Completed
2
42
US
Docetaxel, AvaTax, Bevacizumab
Dana-Farber Cancer Institute, Brigham and Women's Hospital, Massachusetts General Hospital, Beth Israel Deaconess Medical Center, Genentech, Inc., Sanofi
Esophageal Cancer, Gastric Cancer
09/06
09/09
NCT00084604: Irinotecan, Cisplatin, and Bevacizumab in Treating Patients With Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma

Completed
2
47
US
irinotecan hydrochloride, Campto, Camptosar, CPT-11, irinotecan, U-101440E, bevacizumab, anti-VEGF humanized monoclonal antibody, anti-VEGF monoclonal antibody, Avastin, rhuMAb VEGF, cisplatin, CACP, CDDP, CPDD, DDP, computed tomography, tomography, computed, laboratory biomarker analysis
National Cancer Institute (NCI)
Adenocarcinoma of the Gastroesophageal Junction, Diffuse Adenocarcinoma of the Stomach, Intestinal Adenocarcinoma of the Stomach, Mixed Adenocarcinoma of the Stomach, Recurrent Gastric Cancer, Stage IIIA Gastric Cancer, Stage IIIB Gastric Cancer, Stage IIIC Gastric Cancer, Stage IV Gastric Cancer
10/07
 
NCT00394433: Docetaxel, Cisplatin, Irinotecan and Bevacizumab (TPCA) in Metastatic Esophageal and Gastric Cancer

Completed
2
38
US
Bevacizumab, Avastin, Docetaxel, Taxotere, Docefrez, Cisplatin, Platinol-AQ, Platinol, Irinotecan, Camptosar
Dana-Farber Cancer Institute, Brigham and Women's Hospital, Massachusetts General Hospital, Genentech, Inc.
Esophageal Cancer, Stomach Cancer
11/08
10/16
OSI3650, NCT00442507: Erlotinib and Avastin in Patients With Cancer of the Esophagus or Gastroesophageal Junction

Terminated
2
6
US
Erlotinib, Avastin
Washington University School of Medicine
Esophageal Neoplasms, Esophageal Diseases
01/09
01/09
NCT00636298: Study of Cetuximab and Bevacizumab in Cancer of the Esophagus After Failure of Patient's First Therapy

Withdrawn
2
0
US
Bevacizumab, cetuximab
Emory University, Genentech, Inc.
Esophageal Carcinoma
03/10
03/12
NCT00570531: Phase II Trial for Patients With Loco-Regional Esophageal Carcinoma

Terminated
2
6
US
Bevacizumab, Avastin, Paclitaxel, Cisplatin, 5-Fluorouracil, Radiation Therapy, Esophagectomy
University of Michigan Rogel Cancer Center, Genentech, Inc.
Loco-regional Esophageal Cancer
10/10
06/13
NCT00390416: Study of Docetaxel, Cisplatin, and Fluorouracil (Modified DCF) With Bevacizumab in Patients With Unresectable or Metastatic Gastroesophageal Adenocarcinoma

Completed
2
48
US
Docetaxel, Cisplatin, Fluorouracil, Bevacizumab, Leucovorin
Memorial Sloan Kettering Cancer Center, Sanofi, Genentech, Inc.
Stomach Neoplasms, Esophageal Neoplasms
01/12
01/12
NCT00217581: Bevacizumab, Oxaliplatin, and Docetaxel in Treating Patients With Locally Advanced Unresectable or Metastatic Stomach or Gastroesophageal Junction Cancer

Completed
2
39
US
Bevacizumab, Avastin, Docetaxel, Taxotere, Oxaliplatin, Eloxatin
Barbara Ann Karmanos Cancer Institute, National Cancer Institute (NCI)
Esophageal Cancer, Gastric Cancer
11/12
01/13
XAGastric, NCT00447330: Oxaliplatin, Capecitabine and Avastin for Metastatic Esophagogastric Adenocarcinoma

Checkmark capecitabine, oxaliplatin, and bevacizumab in met esophagogastric adenocarcinomas
Mar 2013 - Mar 2013: capecitabine, oxaliplatin, and bevacizumab in met esophagogastric adenocarcinomas
Completed
2
60
US
capecitabine (Xeloda), oxaliplatin and bevacizumab (Avastin)
Duke University, Hoffmann-La Roche, Sanofi, Genentech, Inc.
Esophageal Neoplasms, Stomach Neoplasms, Neoplasm Metastasis
01/14
07/14
NCT00737438: Pre-operative Chemotherapy Plus Bevacizumab With Early Salvage Therapy Based on PET Assessment of Response in Patients With Locally Advanced But Resectable Gastric and GEJ Adenocarcinoma

Checkmark ASCO-GI 2013
Jan 2013 - Jan 2013: ASCO-GI 2013
Completed
2
22
US
epirubicin, cisplatin, capecitabine, bevacizumab, docetaxel and irinotecan, Patients who have a poor PET response to cycle 1 of ECX plus bevacizumab, (eg. < 35% FDG reduction on the week 3 PET scan compared with baseline), will be switched to salvage therapy of docetaxel and irinotecan (DI)., This treatment will be administered on week 1 and 2 of a 3, week cycle for 2 cycles. Patients will receive bevacizumab for the 1st cycle, of salvage docetaxel/irinotecan only. There is again a planned 10-12 week time, interval (eg. 70-84 days) between the last bevacizumab treatment and surgery.
Memorial Sloan Kettering Cancer Center, Genentech, Inc., Weill Medical College of Cornell University
Esophageal Cancer, Gastric Cancer
02/15
02/15
NCT00354679: Irinotecan, Cisplatin, Bevacizumab, Radiation Therapy, and Surgery in Treating Patients With Locally Advanced Esophageal Cancer

Checkmark P2 data-ASCO
Jun 2012 - Jun 2012: P2 data-ASCO
Checkmark Data-ASCO-GI
Jan 2012 - Jan 2012: Data-ASCO-GI
Completed
2
34
US
bevacizumab, cisplatin, irinotecan hydrochloride, proteomic profiling, diagnostic laboratory biomarker analysis, mass spectrometry, adjuvant therapy, neoadjuvant therapy, therapeutic conventional surgery, radiation therapy
Memorial Sloan Kettering Cancer Center, National Cancer Institute (NCI)
Esophageal Cancer
06/15
06/15

Download Options